Condition: Primary Membranous Nephropathy · Sponsor: First Affiliated Hospital, Sun Yat-Sen University
This is a prospective, randomized, multicenter, controlled trial. One hundred sixteen patients with primary membranous nephropathy (PMN) will be randomly divided into the intervention and control groups. The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD. Control patients will be administered maximum tolerable dose of ACEI/ARB. The primary endpoint is the relative change in urinary protein content from baseline to 6 months.
This description comes directly from the study's public registry record.
Wei Chen · 8602087769673 · chenwei99@mail.sysu.edu.cn
Qiong Wen · 8602087769673 · wenqiong@mail.sysu.edu.cn
Always discuss trial participation with your own doctor first.
| Wei Chen | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06573411